Exploring the effects of nitroxyl in a type of bacteria.
Official title: Adminstrative Supplement-Chemical Biology of Nitroxyl (HNO) in Bacillus Subtilis
Funded at Wake Forest University · NIH-11043171 · Data updated 2026-11-12
This study is looking at how a special chemical called nitroxyl interacts with a common bacteria, Bacillus subtilis, to see if it can help fight off antibiotic-resistant infections, which could lead to better treatments for patients in the future.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $17,890 |
| NIH project number | 3R15GM151698-01S1 |
| Project ID | NIH-11043171 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals suffering from infections caused by antibiotic-resistant bacteria.
✕Less likely to help
Patients with infections that are not caused by bacteria or those who do not have antibiotic-resistant strains may not benefit from this research.
What this research studies
This research investigates the chemical biology of nitroxyl (HNO) in Bacillus subtilis, a type of bacteria. The project aims to understand how nitroxyl interacts with bacterial enzymes and its potential role in inhibiting antibiotic-resistant strains. By utilizing various biochemical techniques, the research seeks to uncover the mechanisms by which nitroxyl may affect bacterial growth and metabolism. Patients may benefit indirectly through advancements in antibiotic treatments that could arise from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for combating antibiotic-resistant bacterial infections.
How similar studies have gone: Other research has shown promise in using chemical biology approaches to develop new antibiotics, suggesting potential success for this novel investigation.
Where this research is happening
-
Wake Forest University
Winston-Salem, United States Active
Researchers
- Principal investigator: King, S Bruce — Wake Forest University
- Study coordinator: King, S Bruce
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.